XML 30 R23.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Loss Per Share | 6 Months Ended
--- | ---
Jun. 30, 2024
Earnings Per Share [Abstract] |
Loss Per Share | 15. Loss per share Basic loss per share is calculated by dividing the loss attributable for the year to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is based on dividing the loss attributable for the year, adjusted for the effect of dilutive ordinary shares, by ordinary share equivalents, which includes the weighted average number of ordinary shares outstanding and the effect of dilutive ordinary share equivalents.
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |
Net loss |  | $ | (12,255 | ) |  | $ | (1,751 | ) |  | $ | (21,208 | ) |  | $ | (13,827 | )
Net loss per share - basic and diluted |  | $ | (0.02 | ) |  | $ | (0.00 | ) |  | $ | (0.03 | ) |  | $ | (0.02 | )
Weighted-average number of shares used in computing net loss per share - basic and diluted |  |  | 711,770,804 |  |  |  | 628,421,064 |  |  |  | 706,407,371 |  |  |  | 626,185,695 |
The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect for the three and six months ended June 30, 2024 and 2023 would be to reduce the net loss per share. Therefore, the weighted average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
|  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |
Options |  |  | 73,698,315 |  |  |  | 64,289,090 |
RSUs |  |  | 2,640,115 |  |  |  | 2,738,750 |
PSUs |  |  | 2,676,300 |  |  |  | 6,690,750 |
DRSUs |  |  | 4,276,875 |  |  |  | 3,637,905 |
Convertible loan notes – Novartis |  |  | 16,308,364 |  |  |  | 15,000,137 |
Convertible loan notes – private placement |  |  | - |  |  |  | 24,279,659 |
Warrants to purchase ordinary shares |  |  | 7,539,129 |  |  |  | 7,539,129 |
AstraZeneca milestones potentially payable in equity |  |  | 1,349,692 |  |  |  | 1,349,692 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration